HSP90AA1 and non-small cell lung carcinoma: Thus, heat shock protein 90 (Hsp90) inhibitors with non-targeted therapies with broad-spectrum effects demonstrated advantages in overcoming drug resistance, which would be another choice for NSCLC patients with drug resistance.